股票代码:300558 股票简称:贝达药业 公告编号:2017-027 贝达药业股份有限公司 关于和 Xcovery 公司就全球多中心Ⅲ期临床试验(中国区)合作 暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、本次和 Xcovery Holding Company LLC 就全球多中心Ⅲ...
Welcome to Xcovery, an evidence-based, innovation-driven pharmaceutical company aiming to improve the lives of people around the world living with advanced stages of cancer. Ensartinib: Potentially the best-in-class ALK inhibitor ALK (anaplastic lymphoma kinase) is a receptor tyrosine kinase that ...